Judo Bio launched on Monday with $100 million in funding.
Judo Bio
Halloween is behind us, and as we come out of our sugar-induced comas, it’s time to look at the VC scene in Boston. In September, the cumulative VC funding for Boston area startups was $761.8 million, more than a healthy rise from the previous sluggish month. In October, that VC dollar increase kept climbing as the startup ecosystem saw a total of $1.16 billion from VC funds. As has been the case in the last few roundups, most of the $1.16 billion went to biotechnology companies, with some money finding its way toward tech.
Read about all the October deals here, and be sure to sign up for The Beat, BostInno’s free daily innovation newsletter, so you never miss a thing.
- Triveni Bio Inc. brought in a $115M Series B financing led by Goldman Sachs Alternatives.
- Boston-based Vizit raised a $25 million Series B round led by Industry Ventures.
- Biological Lattice Industries Corp., a Boston-based biotechnology company, successfully closed a $1.8M pre-seed investment round led by Greek venture capital firm Uni.Fund.
- Passkey Therapeutics Inc., a Cambridge-based biotech, emerged from stealth mode to announce $20M in seed funding.
- AvenCell Therapeutics Inc. raised $112M in its Series B round. Alongside lead investor Novo Holdings, other investors included Blackstone Life Sciences, F-Prime Capital and NYBC Ventures.
- Tour24 announced its $5M Series B round led by real estate technology venture capital firm RET Ventures.
- Judo Bio might be a preclinical company, but it’s already brought in $100M in initial financing from its seed round and a recently closed Series A.
- City Therapeutics Inc., a new Cambridge startup, raised a $135 million Series A financing led by Arch Venture Partners.
- According to a Form D filing, Treeline Biosciences, a Watertown-based biotech, has raised another $421.8M.
- Seaport Therapeutics closed a $225 million Series B round after launching with $100 million earlier this year, bringing its total funding to $325 million.
